Servier’s American cancer experiment
How Servier has built out its cancer capabilities and U.S. presence
A string of deals, including two over $1 billion, have given Servier a cancer focus with programs across four modalities and a growing presence in the U.S.
Six years after Servier made its decision to pivot to cancer, the French pharma is on the cusp of being a major player in the space. Through a flurry of deals, the company has added capabilities across at least three modalities and an internal discovery and translational research engine with a fast-growing presence in the U.S.
The private company has its roots in the cardiovascular and diabetes space where it